The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
Biosynth announced on July 11, 2023 that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer-based drug delivery excipients, according to a company press release. The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
“celares is an established leader in bioconjugation, and we are extremely excited to be acquiring such a great team of specialists. celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery,” said Urs Spitz, PhD, CEO and president of Biosynth, in a press release. “Together, we can support customers from development to commercialization. celares is a perfect fit for Biosynth—where chemistry meets biology.”
“We are thrilled to have joined the Biosynth group,” added Ralf Kraehmer, PhD, managing director of celares, in a press release. “As established leaders in bioconjugation, celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward-looking technologies. Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development. We see great similarities in Biosynth with their customer led strategy and passion for the life science industry.”
Source: Biosynth
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.